Eli Lilly and Co. stock gains after Berenberg raises price target on obesity drug growth

Eli Lilly and Co. stock (ISIN US5324571083) is trading near USD 1,152 on the New York Stock Exchange as of September 17, 2026, after a fresh upgrade by Berenberg signaled continued confidence in the company’s obesity-drug business and research productivity.

Analyst upgrade sharpens upside for Eli Lilly

According to Aktiencheck on September 18, 2026, Berenberg upgraded Eli Lilly and Co. from Hold to Buy and raised its price target from USD 1,220 to USD 1,400, citing sustained growth in the obesity-treatment market and attractive returns on capital from the company’s R&D investments.

This move implies a potential upside of about 15 percent to 20 percent from the recent price zone around USD 1,152, underscoring how strongly the bank believes the obesity franchise can expand further compared with its earlier expectations at USD 1,220.

Stock trades above USD 1,150 amid moderate-buy consensus

As MarketBeat reported on September 18, 2026, Eli Lilly and Co. shares opened at USD 1,152.13, reflecting a recent 1.3 percent gain and placing the stock comfortably above the USD 1,100 mark.

According to MarketBeat on September 17, 2026, Eli Lilly and Co. shares rose 1.3 percent to USD 1,152.13, with trading volume around 38 percent below the average, while the firm noted a consensus rating of Moderate Buy and an average price target of USD 1,304.86.

The same MarketBeat overview states that one analyst currently rates the stock Strong Buy, twenty-five give it a Buy rating, three assign Hold and one issues a Sell recommendation, illustrating a broadly positive but not unanimous view of Eli Lilly and Co. among covering brokerages.

Revenue growth and obesity drugs underpin the story

In its latest reported quarter, Eli Lilly and Co. delivered strong top-line momentum, which is a key part of the bullish analyst narrative. According to MarketBeat, the company’s most recent quarterly revenue rose 47.7 percent year over year to USD 22.97 billion, a pace that outstripped expectations and highlighted how fast its newer therapies, particularly in obesity treatment, are scaling.

This near-50 percent revenue increase compared with the prior-year quarter demonstrates how sharply Eli Lilly and Co. has accelerated its growth profile, providing a basis for higher price targets like Berenberg’s new USD 1,400 compared with the previous USD 1,220.

Analyst estimates also reflect the expectation that this momentum will continue. As the analyst overview on Yahoo Finance shows, the average revenue estimate for the current year 2026 stands at USD 88.21 billion, compared with USD 24.21 billion reported EPS in the prior year and an EPS estimate of USD 36.73 for 2026, indicating that analysts expect both top-line and bottom-line expansion versus 2025.

Valuation, risks and competition in cardiometabolic drugs

While the upgrade and strong revenue growth support Eli Lilly and Co. stock, there are also risks and a competitive backdrop that investors need to weigh. As StockStory noted on September 18, 2026, Eli Lilly trades around USD 1,151 per share, corresponding to roughly 27.9 times forward earnings, a premium valuation that leaves less room for error if growth in obesity and diabetes drugs or other franchises slows.

Competitive dynamics in cardiometabolic medicine also represent a meaningful risk. As Yahoo Finance reported on September 17, 2026, a failed cholesterol drug at a rival raises the stakes for peers such as Eli Lilly and Co., which are also competing in cardiovascular and metabolic disease treatment and could face both clinical and regulatory uncertainties as they expand their pipelines.

Despite these challenges, hedge fund interest has remained strong. The same Yahoo Finance piece notes that hedge fund holders in Eli Lilly and Co. increased to 152 from 132 over a recent period, with position value rising to USD 17.24 billion from USD 12.58 billion, suggesting that institutional investors are still willing to back the company despite valuation and pipeline risks.

Earnings expectations and next catalysts

Analyst consensus figures point to further earnings growth in the near term. Per the earnings estimate table on Yahoo Finance dated September 17, 2026, the average EPS estimate for the current quarter ending September 2026 is USD 9.87, compared with USD 7.02 in the year-ago quarter, while the current year 2026 EPS estimate stands at USD 36.73 versus USD 24.21 in the prior year.

This implies expected EPS growth of roughly 40 percent for 2026 relative to 2025, in line with the strong revenue trajectory and reinforcing why some brokerages, such as Berenberg with its USD 1,400 price target compared with USD 1,220 previously, are comfortable projecting further upside for Eli Lilly and Co. stock.

For the following year, the same analyst consensus points to an average EPS estimate of USD 47.32 for 2027, up from the current-year estimate of USD 36.73, which would represent another step-up in profitability if achieved.

Stock level and investor takeaway

Per recent MarketBeat price data as of September 17, 2026, Eli Lilly and Co. stock closed around USD 1,152.13 on the New York Stock Exchange, with the latest move of 1.3 percent placing it within reach of recent highs while still below the average analyst target of USD 1,304.86 and Berenberg’s upgraded USD 1,400 level.

More news and analyses on Eli Lilly and Co. stock